share_log

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D：超过5%持股股东披露文件-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%)等
美股SEC公告 ·  04/19 16:36

Moomoo AI 已提取核心信息

On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
2024年4月12日，据报道，专门从事医疗诊断技术的公司T2 Biosystems, Inc. 的所有权发生了重大变化。由内森·哈基尔领导的一个集团，包括CR集团有限责任公司和CRG Partners的各种基金，向美国证券交易委员会提交了附表13D，表示他们共同收购了T2 Biosystems4％的受益所有权。此次收购是以普通股换取债务取消协议的结果，该协议此前已在附表13G的文件中进行了报告。该集团的实益所有权超过了20％的门槛，触发了附表13D的申报要求。收购这些股票是出于投资目的，目的是增加他们对T2 Biosystems的投资价值。该集团将来可能会考虑收购更多股份或出售其持有的股份。该集团的主要业务是以医疗保健为重点的投资，在过去五年中，他们没有参与任何与证券法有关的法律诉讼。
2024年4月12日，据报道，专门从事医疗诊断技术的公司T2 Biosystems, Inc. 的所有权发生了重大变化。由内森·哈基尔领导的一个集团，包括CR集团有限责任公司和CRG Partners的各种基金，向美国证券交易委员会提交了附表13D，表示他们共同收购了T2 Biosystems4％的受益所有权。此次收购是以普通股换取债务取消协议的结果，该协议此前已在附表13G的文件中进行了报告。该集团的实益所有权超过了20％的门槛，触发了附表13D的申报要求。收购这些股票是出于投资目的，目的是增加他们对T2 Biosystems的投资价值。该集团将来可能会考虑收购更多股份或出售其持有的股份。该集团的主要业务是以医疗保健为重点的投资，在过去五年中，他们没有参与任何与证券法有关的法律诉讼。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间